Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Recruiting

Phase 2

Bortezomib & DexamethasoneBortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Sponsor:

Sparrow Regional Cancer Center

Code:

NCT00389701

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

bortezomib

dexamethasone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-10. This information was provided to ClinicalTrials.gov by Sparrow Regional Cancer Center on 2014-01-10.